LungLife AI, INC Enrolment completed for LungLB(R) validation study (2575A)
23 Maio 2023 - 3:00AM
UK Regulatory
TIDMLLAI
RNS Number : 2575A
LungLife AI, INC
23 May 2023
LungLife AI, Inc.
(the "Company" or "LungLife")
Enrolment completed for pivotal validation study of
LungLB(R)
Company to work with clinical sites to ensure data quality ahead
of analysis and readout
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, announces the completion of enrolment
for its prospective, pivotal validation study of LungLB(R). Since
February 2022, 425 study participants have been enrolled from
seventeen sites across the United States from leading academic
medical centres and Veterans Affairs hospitals.
The Company is now focused on preparing the data for detailed
analysis, including working with each clinical site to finalise
monitoring of study data before it is unblinded. Monitoring ensures
complete, accurate, and high-quality information will be received
for all participants in the study prior to final analyses and
results interpretation. In line with expectations, the Company
estimates this process will take between 3-4 months, at which point
the study results are expected to be known. Following this, the
Company will seek to publish the study findings in a peer-reviewed
medical journal.
Commenting, Paul Pagano, Chief Executive Officer of LungLife,
said : "Completing enrolment is a considerable milestone along the
path to commercialisation, and we are pleased that we continue to
remain on-track with the timeline set out at IPO. We would like to
thank our clinical investigators and their teams, and importantly
the study participants, for taking part in our trial and for their
continued support with study close-out."
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Broker)
Virginia Bull / Cameron MacRitchie
/ Lydia Zychowska
Goodbody (Joint Broker) Tel: +44 (0) 20 3841 6202 / +353 (1)
667 0420
Tom Nicholson / Stephen Kane
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Stephanie Cuthbert / Alice Woodings Mob: 07980 541 893 / 07407 804 654 /
/ Phillip Marriage 07867 984 082
About LungLife
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to
lung cancer. And our Vision is to invert the 20:80 ratio such that
in years to come at least 80% of lung cancer is detected early.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESBRGDUUBDDGXD
(END) Dow Jones Newswires
May 23, 2023 02:00 ET (06:00 GMT)
Lunglife Ai (LSE:LLAI)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Lunglife Ai (LSE:LLAI)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
